Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series.
Pharmaceuticals (Basel)
; 17(1)2023 Dec 24.
Article
en En
| MEDLINE
| ID: mdl-38256862
ABSTRACT
(1) Background:
Increasing evidence supports the anti-inflammatory and neuroprotective role of perampanel (PER), mediated by decreased expression of pro-inflammatory cytokines and by interference with apoptosis processes. Therefore, the use of PER to treat status epilepticus (SE) with suspected inflammatory etiology is appealing and deserves further investigation. (2)Methods:
We retrospectively analyzed seven patients (five F, two M; median age 62 years) with refractory and super-refractory SE due to a probable or defined inflammatory etiology and treated with PER. (3)Results:
PER was administered as the third (4/7) or fourth drug (3/7), with a median loading dose of 32 mg/day (range 16-36 mg/day) and a median maintenance dose of 10 mg/day (range 4-12 mg/day). In five cases, SE was focal, while in two patients, it was generalized. SE was caused by systemic inflammation in three patients, while in the other four subjects, it was recognized to have an autoimmune etiology. SE resolution was observed after PER administration in all cases, particularly within 24 h in the majority of patients (4/7, 57.1%). (4)Conclusions:
Our data support the efficacy of PER in treating SE when first- and second-line ASMs have failed and suggest a possible earlier use in SE cases that are due to inflammatory/autoimmune etiology.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Etiology_studies
Idioma:
En
Revista:
Pharmaceuticals (Basel)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Italia